Search research articles
Contact Us
Filters
Showing results (351-360 of 361) with videos related to
Page
of 37
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood
|
October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Surbhi Sidana, Krina K Patel, Lauren C Peres, et al.
The New England Journal of Medicine
|
June 6, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
The New England Journal of Medicine
|
May 11, 2012
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L McCarthy, Kouros Owzar, Craig C Hofmeister, et al.
The Lancet. Haematology
|
August 23, 2017
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Sarah A Holstein, Sin-Ho Jung, Paul G Richardson, et al.
Blood
|
May 13, 2025
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells
Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Research Square
|
May 19, 2023
Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial
Angela Branche, Nadine Rouphael, David Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 6, 2026
Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy
John V Pluvinage, David Acero-Garces, Giacomo Greco, et al.
Page
of 37
Search research articles
Search
Showing results (351-360 of 361) with videos related to
Sort By:
Page
of 37
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood
|
October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Surbhi Sidana, Krina K Patel, Lauren C Peres, et al.
The New England Journal of Medicine
|
June 6, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
The New England Journal of Medicine
|
May 11, 2012
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L McCarthy, Kouros Owzar, Craig C Hofmeister, et al.
The Lancet. Haematology
|
August 23, 2017
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Sarah A Holstein, Sin-Ho Jung, Paul G Richardson, et al.
Blood
|
May 13, 2025
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells
Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Research Square
|
May 19, 2023
Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial
Angela Branche, Nadine Rouphael, David Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 6, 2026
Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy
John V Pluvinage, David Acero-Garces, Giacomo Greco, et al.
Page
of 37